Survodutide
BI 456906 · Boehringer Ingelheim dual agonist
Popular for:Weight loss, MASH/NASH liver disease, dual GLP-1/glucagon agonist
59
Total Studies
38
Human Studies
Phase III
Evidence Level
Investigational
FDA Status
Overview
Survodutide is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim, currently in Phase III clinical trials for obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). It represents a different dual-agonist approach than tirzepatide — instead of GLP-1/GIP, survodutide combines GLP-1 with glucagon receptor activation.
The glucagon component is significant: while it may seem counterintuitive to activate a hormone that raises blood sugar, glucagon receptor activation increases hepatic fat oxidation and energy expenditure. Phase II results showed up to 19% weight loss and significant liver fat reduction, making it a promising candidate for both obesity and fatty liver disease.
Mechanism of Action
Survodutide activates both GLP-1 and glucagon receptors. The GLP-1 component reduces appetite, slows gastric emptying, and improves insulin secretion. The glucagon component increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. This dual action produces weight loss through both reduced intake (GLP-1) and increased expenditure (glucagon) while specifically targeting liver fat accumulation — a mechanism neither pure GLP-1 nor GLP-1/GIP agonists achieve as effectively.
Key Research Benefits
Clinical Evidence Summary
Research Pipeline
59
Total Studies
38
Human Studies
Investigational — Phase III clinical trials ongoing (Boehringer Ingelheim). Not available outside clinical trials. Potential regulatory submission expected 2027-2028.
Key Studies / PubMed References
59 studies found on PubMed · showing top 25 by relevance
View all on PubMedSurvodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).
Human Studyle Roux CW, Wharton S, Bozkurt B, et al. · Diabetes, obesity & metabolism · 2026
PMID: 41187967Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.
ReviewSon JW, le Roux CW, Blüher M, et al. · Endocrine reviews · 2026
PMID: 41054801Emerging pharmacotherapies for obesity: A systematic review.
Meta-AnalysisKokkorakis M, Chakhtoura M, Rhayem C, et al. · Pharmacological reviews · 2025
PMID: 39952695Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.
ReviewBailey CJ, Flatt PR, Conlon JM · Peptides · 2025
PMID: 40081498The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists.
ReviewAlkhouri N, Charlton M, Gray M, et al. · Expert opinion on investigational drugs · 2025
PMID: 40016997Side Effects & Safety
Known Interactions
No curated interaction entry is live for Survodutide yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Survodutide is not approved by the FDA for human therapeutic use. Always consult a qualified healthcare professional before making any health-related decisions. The studies referenced are linked to their original PubMed sources for verification.